Novartis' Jakavi will be available to patients in Scotland with the bone marrow cancer myelofibrosis after a positive verdict from the Scottish Medicines Consortium (SMC). Jakavi (ruxolitinib ...

Novartis reported sales of Jakavi reached $279 million last year, while development partner Incyte – which sells the drug in the US as Jakafi – booked $358 million from the drug.